The cost impact of PCT-guided antibiotic stewardship versus usual care for hospitalised patients with suspected sepsis or lower respiratory tract infections in the US: A health economic model analysis

Janne C. Mewes¹, Michael S. Pulia², Michael K. Mansour³,4, Michael R. Broyles⁵, H. Bryant Nguyen⁶,⁷, Lotte M. Steuten¹,8,9*¹

¹ Panacea B.V., Amsterdam, the Netherlands, ² BerbeeWalsh Department of Emergency Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, United States of America, ³ Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA, United States of America, ⁴ Harvard Medical School, Boston, MA, United States of America, ⁵ Department of Clinical Pharmacy and Laboratory Services, Five Rivers Medical Center, Pocahontas, AR, United States of America, ⁶ Division of Pulmonary, Critical Care, Hyperbaric and Sleep Medicine, Loma Linda University, Loma Linda, CA, United States of America, ⁷ Department of Emergency Medicine, Loma Linda University, Loma Linda, CA, United States of America, ⁸ Fred Hutchinson Cancer Research Center, Hutchinson Institute for Cancer Outcomes Research, Seattle, WA, United States of America, ⁹ University of Washington, School of Pharmacy, the CHOICE Institute, Seattle, WA, United States of America

* lstuten@fredhutch.org

Abstract

Background

Procalcitonin is a biomarker that supports clinical decision-making on when to initiate and discontinue antibiotic therapy. Several cost-effectiveness analyses have been conducted on Procalcitonin-guided antibiotic stewardship, but none mainly based on US originated data.

Objective

To compare effectiveness and costs of a Procalcitonin-algorithm versus standard care to guide antibiotic prescription for patients hospitalized with a diagnosis of suspected sepsis or lower respiratory tract infection in the US.

Methods

A previously published health economic decision model was used to compare the costs and effects of Procalcitonin-guided care. The analysis considered the societal and hospital perspective with a time horizon covering the length of hospital stay. The main outcomes were total costs per patient, including treatment costs and productivity losses, the number of patients with antibiotic resistance or C.difficile infections, and costs per antibiotic day avoided.
Results

Procalcitonin-guided care for hospitalized patients with suspected sepsis and lower respiratory tract infection is associated with a reduction in antibiotic days, a shorter length of stay on the regular ward and the intensive care unit, shorter duration of mechanical ventilation, and fewer patients at risk for antibiotic resistant or C. difficile infection. Total costs in the Procalcitonin-group compared to standard care were reduced by 26.0% in sepsis and 17.7% in lower respiratory tract infection (total incremental costs of −$11,311 per patient and −$2,867 per patient respectively).

Conclusions

Using a Procalcitonin-algorithm to guide antibiotic use in sepsis and hospitalised lower respiratory tract infection patients is expected to generate cost-savings to the hospital and lower rates of antibiotic resistance and C. difficile infections.

Background

Antibiotics are essential for treating sepsis and lower respiratory tract infections (LRTI), including pneumonia and COPD exacerbations. Yet, inappropriate prescribing is pervasive and contributes to the development of antibiotic resistance (ABR) and C. difficile infections, and poses an increasing burden on healthcare resources [1, 2].

Antibiotic resistance is considered one of the most pressing health threats globally. In the US, every year 2 million people acquire a bacterial infection that is resistant to at least one antibiotic, causing 23,000 deaths [1]. The healthcare burden of C. difficile infections has also increased during the last decade, as it is becoming more frequent, while at the same time harder to treat [1].

Biomarkers to guide antibiotic treatment decisions have been proposed as an effective and efficient way to enhance the appropriate use of antibiotics. As a biomarker, procalcitonin (PCT) has good specificity to distinguish bacterial from non-bacterial inflammations and could therefore help prevent unnecessary antibiotic prescriptions and/or reduce the duration of antibiotic therapy [2]. PCT can be detected in the blood 3–4 hours after a bacterial stimulus and inflammatory response. PCT reaches its highest concentration after 14–25 hours and has a half-life of 22–35 hours after the bacterial stimulus has been appropriately treated and the inflammatory response begins to resolve. Using a PCT-assay and a PCT-algorithm, clinicians can make appropriate decisions regarding antibiotic usage [3]. Meta-analyses showed that PCT is safe and effective, resulting in reduced antibiotic initiation and shorter antibiotic duration [4]. These benefits however, come at the additional costs of PCT-testing. Cost-effectiveness analyses are therefore needed to evaluate to what extent the health benefits, and their associated cost savings, can offset the added costs of PCT-testing. Several cost-effectiveness analyses based on European data [5–7] have shown increased costs for obtaining PCT-levels, and net savings when considering the downstream cost impacts of PCT-guided ABS on resource utilization. The aim of this paper is to conduct an economic evaluation of PCT from a US societal perspective, using US data when available. Our analyses incorporate direct medical costs, costs of C. difficile infections and antibiotic resistance, as well as productivity losses.
Methods

This literature-based study is a comparative effectiveness and costs analysis of PCT-guided antibiotic stewardship versus standard care for patients with suspected sepsis on the intensive care unit (ICU) and patients hospitalized with LRTI, using a previously published decision tree model [8], as shown in Figs 1 and 2.

The difference between the analysis for sepsis and LRTI and the reason they are presented separately is that the model assumes that all sepsis patients are initially admitted to the ICU and all receive antibiotics initially, which is not the case for LRTI patients. The analysis was conducted from the societal perspective using a time horizon covering the length of the hospital stay.

In PCT-guided care, an algorithm was used to guide the decision of whether to start antibiotic treatment (LRTI) and when to stop administering antibiotics (LRTI and sepsis). Standard care included all usual care but no usage of a PCT-algorithm to guide the decision on when to start or stop antibiotics. The patient population consisted of patients with suspected sepsis in the ICU and patients hospitalised with LRTI. The latter included patients with COPD exacerbations, community-acquired pneumonia (CAP), ventilator-associated pneumonia (VAP), and acute bronchitis. In the model, the yearly number of patients hospitalised in the US with suspected sepsis or LRTI patients was included; 950,000 sepsis patients [9] and 1.9m LRTI patients [10–12].

The main outcome of the analysis were 1) the total difference in costs per patient and by patient population, 2) number of antibiotic days avoided, 3) number of C. difficile infections avoided, and 4) number of antibiotic resistance cases avoided. We also reported the incremental costs per antibiotic day avoided. All outcomes were analysed separately for (suspected) sepsis and LRTI patients.

Data collection

A systematic literature review was conducted to identify studies examining the effectiveness of PCT-guided antibiotic therapy versus standard care. Pubmed was searched using the following search terms: (LRTI OR sepsis OR septic shock OR critically ill OR pneumonia OR bronchitis OR COPD OR bacterial infection) AND (PCT or procalcitonin) AND (antibiotic OR antimicrobial OR "antibiotic stewardship" OR "antibiotic therapy"). Studies to be included had to be published from the year 2000 or later, be conducted in the hospital setting, include adult patients with (suspected) sepsis or LRTI, compare the effect of using a PCT-algorithm for guiding antibiotic therapy to standard care, and contain data on the effect of PCT-guided care on the number of antibiotic days, number of physician visits, hospital length of stay (regular ward and ICU), percentage of patients and number of days on mechanical ventilation, or rates of C. difficile infections and antibiotic resistant infections. Unsystematic and narrative reviews were excluded. US studies were prioritized for inclusion. In case no US data were available, non-US studies were considered, after validating the data’s applicability to the US healthcare setting by US clinician-researchers (MP, MK, MB, and BN). Data that could not be identified in any of the studies included in the literature review was taken from the previous model [8].

The selection of studies was conducted by JCM, MSP, and HBN. Titles and abstracts from our Pubmed search were screened, and full texts were obtained for those meeting our inclusion criteria. Selection was done by consensus. By manually reviewing reference lists of included studies additional citations were identified and included if appropriate.

If US or multi-national studies including US data were available, then US data were extracted from those studies using standardized forms; otherwise European data were extracted. For studies that did not report US-specific estimates, the authors were contacted.
and asked to share the US-specific data. When two or more studies provided data on one parameter, the weighted averages were used. For this purpose, results that were presented as medians and ranges were converted to means and standard deviations. Data on antibiotic use that were presented as days of therapy were converted into antibiotic days, based on the average number of antibiotics used per day requested from the authors. Cost were obtained from published studies and online reports, CMS Fee Schedules, and public databases on health care costs.

**Input data**

The key input parameters for the effectiveness of PCT-guided antibiotic use, including length of stay on the regular ward and on the ICU (days), number of antibiotic days, and duration of mechanical ventilation (days), were derived exclusively from US studies [13–16]. The reduction in antibiotic resistant infections due to PCT-guided antibiotic management was determined by first conservatively estimating the prevalence of ABR in the U.S. population. This was 21.7% in sepsis and 22.2% in LRTI [17]. Based on previously published studies a

**Fig 1. Decision-tree for patients with sepsis.** ABX = Antibiotics.  
https://doi.org/10.1371/journal.pone.0214222.g001

**Fig 2. Decision-tree for patients with LRTI.** ABX = Antibiotics.  
https://doi.org/10.1371/journal.pone.0214222.g002
correlation between the percentage of reduction in antibiotic days and ABR rate of 3.2% was established [18–20] (Steuten, Mewes et al–forthcoming). This rate was multiplied with the reduction in ABR based on the percentage of reduction in antibiotic days (the difference in antibiotic days between the PCT-guided group and usual care divided by the number of antibiotic days in the usual care group) [18–20].

The number of mechanical ventilation days was analysed by multiplying the mechanical ventilation days per 1,000 patient days by length of stay on the ICU [14]. For patients with LRTI, mechanical ventilation days were only applicable for the patients who were admitted to the ICU.

We used previously published European data to estimate the proportion of (suspected) sepsis patients with blood cultures performed and sets of blood cultures taken, number of other laboratory tests performed, and number of PCT measurements. These were confirmed by the co-authors to be similar with US clinical practice. For all effectiveness input parameters and resource use see Tables 1 and 2.

Cost categories included in the decision tree model pertained to costs of hospital stay, treatment costs (including antibiotics and mechanical ventilation), laboratory analyses (including blood cultures, PCT tests, and other laboratory tests), antibiotic resistant infections, C. difficile infections, and productivity losses. The latter were calculated by multiplying the number of days in hospital by the productivity costs for an 8-hour workday. Costs of C. difficile infections and ABR consisted of costs for extended length of stay and additional blood and diagnostic tests during the extended stay.

All costs were based on US-data and converted to 2017 US dollars using the CPI inflation calculator. Discounting was not required as the time horizon of the model is shorter than one year. See Table 3 for the cost inputs.

Analysis
In the decision tree, antibiotic days avoided were evaluated for two treatment pathways, PCT-guided antibiotic use and standard care. Costs were assigned to each pathway in the model. For every cost item included (costs of the hospital stay, antibiotic treatment, mechanical ventilation, laboratory analyses including PCT test, costs of antibiotic resistance and C. difficile infections, and productivity losses) the costs were calculated by multiplying the volumes used by the unit costs. This was done for every cost item and finally added up into a total cost for PCT-guided care and a total cost for standard care. Incremental costs per patient were calculated by subtracting the costs for the standard care strategy from the expected costs of the PCT-guided strategy. Total costs on a population level were analysed by multiplying the annual number of hospitalised patients with (suspected) sepsis or LRTI with the expected total costs per patient for each strategy. The number of patients with C. difficile infection or antibiotic resistant infection were estimated by multiplying the event probabilities (the percentage of patients to whom an event applies, e.g. the percentage of patients with LRTI who are on the ICU) by the size of the patient population. Incremental costs per antibiotic day avoided were calculated by dividing the incremental costs per patient by the absolute incremental number of antibiotic days. See S1 and S2 Tables for the calculations.

Sensitivity & scenario analysis
To test the robustness of the results and to identify the key cost drivers of the model, all parameters were varied by +/- 25%. Additionally, best- and worst-case scenario analyses were conducted by using the lowest and highest differences between usual care and PCT-guided treatment found in the literature for the length of stay and the number of antibiotic days, and,
for LRTI, the percentage of patients receiving antibiotics. The lowest and highest values identified in the literature for these parameters were used. In the worst-case scenario, no difference in length of stay (LOS) between PCT-guided ABS and standard care is modelled [36]. For sepsis, a difference in antibiotic days of -3.3 is used [14] and for LRTI of -2.25 [13]. Further, for
LRTI patients, no difference in the percentage of patients receiving antibiotics is modelled in the worst-case scenario [16]. For the best-case scenario, the difference in the length of stay on the regular ward is increased to -1.5 days [29], while the ICU stay remains the same as in the base case (i.e. as in the main analysis as described in the methods), since a higher difference was not identified in the literature. The incremental antibiotic days modelled are -6.0 for sepsis and LRTI [15], and the difference in percentage of patients on antibiotics is set at -17%, based on the difference found by Stolz et al. (2009) between 7 and 14 days of antibiotic use [16].

### Results

#### Systematic review

The literature search in Pubmed yielded 838 articles. Based on review of titles and abstracts, the full texts of 81 articles were obtained. Of these, 25 articles were excluded. The hand search yielded 4 additional studies resulting in a total selection of 60 articles. Of these, 13 articles reported the results of US-studies [4–7, 13–16, 29, 36–39]. Three of these were multi-country
studies including the US [4, 16, 39], and three articles were primarily economic analyses [10–12]. See the flow chart in Fig 3.

Results for sepsis
Based on the model’s outcomes, PCT-guided ABS reduced the antibiotic duration by 5.83 days in the PCT-group. LOS on the general ward was -0.7 days and on the ICU -3.6 in PCT-guided care versus standard care. The incremental costs (the difference in costs between the two groups) per patient were -$11,311 in the PCT-guided group including productivity losses (Table 4). Therefore, the incremental costs per antibiotic day avoided were -$1,939 (which is the incremental cost per patient divided by the absolute difference in antibiotic days).

On the patient population level, the incremental costs for PCT-guided care were -$10,745,997,485. The number of sepsis patients with antibiotic resistant infections in hospital was estimated to be 6.4% lower in PCT-guided care than in standard care, with 206,442 versus 193,219 patients, respectively. The number of hospital C. difficile infections in PCT-guided care was estimated to be 54.8% lower than in standard care, with 13,272 versus 29,375 C. difficile infections, respectively. See Table 4.

Results for LRTI
In the PCT-group, the number of antibiotic days avoided was 4.91 per patient. LOS on the general ward was -0.7 days and on the ICU -3.6 in PCT-guided care versus standard care. The incremental total costs (the difference in costs between the two groups) per LRTI patient, including productivity losses, were -$2,867. Therefore, the incremental costs per antibiotic day avoided were -$584 (which is the incremental cost per patient divided by the absolute difference in antibiotic days).

For the whole LRTI patient population the incremental total costs were -$5,443,681,261. The number of patients with ABR in hospital was estimated to be 17.4% lower in PCT-guided care with 305,174 resistant infections compared to 369,639 resistant infections in standard care. The number of patients with hospital C. difficile infection in standard care was estimated to be 51,486 and 19,999 in PCT-guided care, which is a reduction of 61.2%. See Table 4.

Sensitivity & scenario analysis
The one-way sensitivity analysis showed that the model results for the sepsis population are most sensitive to 1) effect on ICU days and costs per ICU day, 2) the costs per general ward day, and 3) the effect on general ward days. For LRTI, these were 1) the cost per general ward day, 2) the effect on general ward days, and 3) the percentage of patients receiving antibiotics. The tornado diagrams in Figs 4 and 5 show the ten most influential parameters for sepsis and LRTI, respectively.

In the worst-case scenario, for both sepsis and LRTI, the total incremental costs remained in the cost-saving range, with -$3,416 and -$554, respectively. These cost savings resulted from fewer days on antibiotics, leading to lower costs for antibiotics and fewer patients with ABR and C. difficile infections. In the best-case scenario, the cost savings increased to -$12,345 for sepsis and to -$4,201 or LRTI.

Discussion
We evaluated the comparative effectiveness and the costs of PCT-guided ABS versus usual care for sepsis and LRTI patients from the US societal perspective. To the best of our knowledge this is the first cost analysis that is mainly based on US studies. For both patient groups,
PCT-guided ABS is expected to reduce antibiotic exposure and to lead to substantially lower societal costs. In addition, the model projected reductions in the number of patients with ABR and *C. difficile* infections.

The incremental total costs, including treatment costs and productivity losses, amounted to -$11,311 per sepsis patient, implying cost-savings in the PCT-group. For LRTI patients, the incremental total costs were -$2,867 per patient in the PCT-group compared to usual care.

Given the large numbers of sepsis and LRTI patients, the yearly cost-savings from the US perspective are substantial; -$10.7billion for sepsis and -$5.4billion for LRTI. Projected reductions in ABR and *C. difficile* infections were 6.4% and 54.8% for sepsis and 17.4% and 61.2% for LRTI, respectively. The cost-savings were mainly driven by the reduction in LOS and the reduced number of patients with ABR in patients with LRTI. For patients with sepsis, savings were driven by a shorter LOS and reduced costs for mechanical ventilation. The results of the scenario analysis showed that even in the most conservative scenarios, cost-savings were realised.

Previous economic and cost analyses have been conducted for the US of PCT to guide antibiotic therapy. The study by Harrison et al. (2015) [7] analysed the cost impact of PCT for adult ICU patients suspected of sepsis or bacterial infection from the US hospital perspective, with effectiveness data (among others) being based on a French study, reviews, and meta-analyses. The total costs in standard care were $40,663 versus $40,597 in PCT-guided ABS, with cost-savings of $65 in PCT. This study found comparable total costs to our results, but a much smaller cost difference. The larger cost difference in our study is caused by the difference in LOS that we included in our model.
Smith et al. (2013) [6] evaluated the costs per quality-adjusted life year for patients hospitalised with community-acquired pneumonia. Different from our analysis, only antibiotic use and antibiotic costs were assumed to differ between the PCT and the standard care group. It

Table 4. Results for patients with sepsis and LRTI.

| Outcome | Standard care | PCT-guided ABS | Difference |
|---------|---------------|----------------|------------|
| SEPSIS  |               |                |            |
| **Effectiveness measures** |               |                |            |
| Antibiotic days | 13.37 | 7.54 | -5.83 |
| Patients with antibiotic resistant infection | 206,441.76 | 193,218.28 | -13,222.48 |
| *C. difficile* infections | 29,374.58 | 13,271.51 | -16,103.07 |
| **Cost outcomes** |               |                |            |
| Hospital stay | $30,087.16 | $22,382.42 | -$7,704.75 |
| Antibiotics | $763.60 | $430.52 | -$333.18 |
| Mechanical ventilation | $5,775.00 | $3,675.00 | -$2,100.00 |
| Lab tests (including PCT tests in the PCT-group) | $1,711.27 | $1,625.63 | -$85.64 |
| Additional costs of antibiotic resistant infection (see S1 Table) | Per patient with ABR: $6,955.31 | Per patient with ABR: $6,786.38 | Per patient with ABR: -$168.94 |
| | Per sepsis patient: $1,511.31 | Per sepsis patient: $1,380.15 | Per sepsis patient: -$131.16 |
| Additional costs of *C. difficile* infection (see S1 Table) | Per patient with CDI: $11,287.72 | Per patient with CDI: $11,287.72 | Per patient with CDI: 0 |
| | Per sepsis patient: $348.99 | Per sepsis patient: $157.68 | Per sepsis patient: -$191.32 |
| Productivity losses per patient | $3,232.90 | $2,468.37 | -$764.54 |
| Average total costs per sepsis patient | $43,430.34 | $32,119.76 | -$11,310.57 |
| Total costs per sepsis patient population | $41,262,479,518 | $30,516,482,033 | -$10,745,997,485 |
| LRTI  |               |                |            |
| **Effectiveness measures** |               |                |            |
| Antibiotic days | 11.90 | 6.99 | -4.91 |
| Patients with antibiotic resistant infection | 369,639.33 | 305,173.70 | -64,465.64 |
| *C. difficile* infections | 51,485.59 | 19,998.90 | -31,486.69 |
| **Cost outcomes** |               |                |            |
| Hospital stay | $9,754.73 | $8,149.72 | -$1,605.02 |
| Antibiotics | $585.87 | $295.90 | -$289.97 |
| Mechanical ventilation | $606.38 | $385.88 | -$220.50 |
| Lab tests (including PCT tests in the PCT-group) | $1,292.32 | $1,361.80 | $69.48 |
| Additional costs of antibiotic resistant infection (see S2 Table) | Per patient with ABR: $11,139.02 | Per patient with ABR: $11,125.20 | Per patient with ABR: -$13.82 |
| | Per LRTI patient: $2,168.45 | Per LRTI patient: $1,788.05 | Per LRTI patient: -$380.40 |
| Additional costs of *C. difficile* (see S2 Table) | Per patient with CDI: $11,287.72 | Per patient with CDI: $11,287.72 | Per patient with CDI: 0 |
| | Per LRTI patient: $306.07 | Per LRTI patient: $118.89 | Per LRTI patient: -$187.18 |
| Productivity losses per patient | $1,503.84 | $1,250.50 | -$253.34 |
| Average total costs per LRTI patient | $16,217,65 | $13,350.73 | -$2,866.92 |
| Total costs per LRTI patient population | $30,793,879,222 | $25,350,197,961 | -$5,443,681,261 |

All results are rounded to two digits. Numbers not adding up are due to rounding.
ABR = Antibiotic resistance, CDI = *C. difficile* infection

https://doi.org/10.1371/journal.pone.0214222.t004
was found that the costs in the PCT group were $22 higher than in usual care. Sensitivity analyses showed that one of the parameters with most influence on total costs is decreased hospital length of stay, which was similar to our results.

Fig 4. Tornado diagram showing the results of the sensitivity analysis for sepsis on the total costs per patient in comparison to the base case values of the main analysis. The tornado diagram shows to what degree changes in an input variable influence the total costs of PCT-guided care. While all other parameters are being held equal, the value of one input parameter is varied by + or − 25%. The tornado diagram shows the difference of this result to the result of the primary analysis, in which the values as defined in the input parameter tables are used.

https://doi.org/10.1371/journal.pone.0214222.g004

Fig 5. Tornado diagram showing the results of the sensitivity analysis for LRTI on the total costs per patient in comparison to the base case values of the main analysis.

https://doi.org/10.1371/journal.pone.0214222.g005
The economic evaluation by Schuetz et al. (2015) [2] assessed the cost-effectiveness of PCT-guided ABS for patients with acute respiratory tract infections from the perspective of a US integrated delivery network. The effectiveness data was based on a meta-analysis and adapted to fit the US-situation. For PCT-guided care, substantial cost-savings of $700,000 were found for a 1m-member catchment-area, supporting our result of cost savings in the PCT-guided group.

For the US, a limited amount of research on the effectiveness of PCT-guided ABS was available. The FDA, for example, cleared high-sensitive PCT for the management of antibiotics in LRTI and sepsis based on a meta-analysis of several European trials, which showed a safe reduction in antibiotic days of -3.2 and a change in length of stay of 1.1 days on the ICU (an increase in the PCT-group) and -1.4 days on the general ward. Still, in our analysis, all but one of the most influential input parameters (according to the sensitivity analysis) were based on US data.

Huang et al. recently published the ProACT study and found no difference for the number of antibiotic days and the number of adverse events [40]. It should be noted that the patient population of the ProACT study differs from the patients with LRTI in our analysis. Whereas we included only hospitalised patients with LRTI, less than half (47%) of the ProACT patients were hospitalised. Further, a third of included patients had a diagnosis of asthma, a non-LRTI where antibiotics are not generally indicated.

Our paper has limitations regarding the data that was used in the model. The data underlying the main parameters in our model were based on either one or a few studies. As a systematic literature review was conducted to identify all data available and suitable for the model, the results show the cost-savings that can be expected given the best evidence available at that time. The study by Bishop et al. (2014) [14], e.g., included 100 participants. Some larger US-studies that were identified in our literature review unfortunately did not provide data that are required for a health economic analysis. For example, while our analysis compared PCT-guided therapy to standard care, many studies compared PCT algorithm-adherent patients to algorithm non-adherent patients [5] or patients with a PCT-value of <0.25ng/mL to patients with a PCT-value ≥0.25ng/mL [36–39]. Regarding antibiotic use, we included the number of antibiotic days in our model, whereas many studies provided the percentage of patients that received antibiotics for longer than 48 hours [36], presented the results as an adjusted risk ratio [37], or summarised results for all patients [38]. In addition, the retrospective study by Balk et al. (2017) [29] was not included in the effectiveness analysis because patients with serial PCT testing after the first day of ICU care were not included in this database, and therefore “it is unlikely that PCT was used to guide early antibiotic discontinuation” (p.32), which was the focus of our model notably for the sepsis population.

For some parameters, data was not available specifically for the US and therefor based on European data. All non-US data used in the model were validated for their applicability to the US healthcare setting by the four clinical authors of this study. From a multi-country study, the US-specific data was requested but not received. The change in antibiotic resistance infections, depending on the change in antibiotic days, was based on two studies. As long-term data are lacking, we conservatively projected the impact on ABR solely based on the reduction in days of AB exposure and LOS. Mortality was not included in our model; however, it should be noted that multiple RCTs established PCT being safe [29]. In a recent, large patient-level meta-analyses including more than 6,700 patients a significant reduction in 30-day mortality was found for PCT use compared to controls [4]. Finally, our model does neither consider the impact of shorter antibiotic duration on bloodstream infections through IV-administration nor include quality-adjusted life years.
Further, while the study by Bishop et al. (2014) [14] is one of the few US studies to date, it presents results for patients with sepsis and patients with LRTI combined. For analysing the cost impact of PCT using data that is completely based on patients with the specific disease, future research should present the results of patients with different diseases separately. Still, the model is based on the best evidence that is currently available. In addition, more US-based research on the effect of PCT-testing is needed to include the results of more studies in the model. Finally, the long term impact of PCT on ABR and *C. difficile* infections, and the impact on other outcomes such as bloodstream infections and health-related quality of life need to be studied.

**Conclusion**

Our results showed that using a PCT-algorithm to guide antibiotic use in sepsis and hospitalised patients with lower respiratory tract infections reduced the total costs, including treatment costs and productivity losses, in the US by $11,311 and $2,867, respectively. The cost drivers were shown to be the patients’ length of stay, the costs of the hospital stay, and, for patients with LRTI, the percentage of patients receiving antibiotics. The number of patients with antibiotic resistance infections and *C. difficile* infections were reduced considerably, however, this was based on very few studies. Considering the growing public health concern related to antibiotic resistance infections and *C. difficile* infections, future investigations should focus on impact of PCT-guided ABS on the number of patients with antibiotic resistance infection and *C. difficile* infection.

**Supporting information**

*S1 Table. Cost calculation for sepsis.*

(DOCX)

*S2 Table. Cost calculation for LRTI.*

(DOCX)

**Acknowledgments**

Previous presentations: This study was presented as a poster at the AACC Annual Scientific Meeting 2018.

**Author Contributions**

**Conceptualization:** Janne C. Mewes, Lotte M. Steuten.

**Data curation:** Janne C. Mewes, Lotte M. Steuten.

**Formal analysis:** Janne C. Mewes.

**Funding acquisition:** Lotte M. Steuten.

**Investigation:** Janne C. Mewes, Michael S. Pulia, Michael K. Mansour, Michael R. Broyles, H. Bryant Nguyen, Lotte M. Steuten.

**Methodology:** Janne C. Mewes, Michael S. Pulia, Michael K. Mansour, Michael R. Broyles, H. Bryant Nguyen, Lotte M. Steuten.

**Project administration:** Janne C. Mewes, Lotte M. Steuten.

**Supervision:** Janne C. Mewes, Lotte M. Steuten.
Validation: Janne C. Mewes, Michael S. Pulia, Michael K. Mansour, Michael R. Broyles, H. Bryant Nguyen, Lotte M. Steuten.

Visualization: Janne C. Mewes.

Writing – original draft: Janne C. Mewes, Lotte M. Steuten.

Writing – review & editing: Janne C. Mewes, Michael S. Pulia, Michael K. Mansour, Michael R. Broyles, H. Bryant Nguyen, Lotte M. Steuten.

References

1. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. Atlanta: U.S. Department of Health and Human Services; 2013.

2. Schuetz P, Balk R, Briel M, Kutz A, Christ-Crain M, Stolz D, et al. Economic evaluation of procalcitonin-guided antibiotic therapy in acute respiratory infections: a US health system perspective. Clin Chem Lab Med. 2015; 53(4):583–92. https://doi.org/10.1515/cclmm-2014-1015 PMID: 25581762

3. Povoa P, Salluh JI. Biomarker-guided antibiotic therapy in adult critically ill patients: a critical review. Ann Intensive Care. 2012; 2(1):32. https://doi.org/10.1186/2110-5820-2-32 PMID: 22824162

4. Schuetz P, Wirz Y, Sager R, Christ-Grain M, Stolz D, Tamm M, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. Lancet Infect Dis. 2018; 18:95–107. https://doi.org/10.1016/S1473-3099(17)30592-3 PMID: 29037960

5. Albrich WC, Dusemund F, Bucher B, Meyer S, Thomann R, Kuhn F, et al. Effectiveness and safety of procalcitonin-guided antibiotic therapy in lower respiratory tract infections in “real life”: an international, multicenter poststudy survey (ProREAL). Arch Intern Med. 2012; 172(9):715–22. https://doi.org/10.1001/archinternmed.2012.770 PMID: 22782201

6. Smith KJ, Wateska A, Nowalk MP, Raymond M, Lee BY, Zimmerman RK, et al. Cost-effectiveness of procalcitonin-guided antibiotic use in community acquired pneumonia. J Gen Intern Med. 2013; 28(9):1157–64. https://doi.org/10.1007/s11606-013-2400-x PMID: 23463457

7. Harrison M, Collins CD. Is procalcitonin-guided antimicrobial use cost-effective in adult patients with suspected bacterial infection and sepsis? Infect Control Hosp Epidemiol. 2015; 36(3):265–72. https://doi.org/10.1086/664764 PMID: 25695167

8. Kip MM, Kusters R, IJzermans MJ, Steuten LM. A PCT algorithm for discontinuation of antibiotic therapy in ventilator-associated pneumonia requiring hospitalization among U.S. adults. N Engl J Med. 2015; 373(5):415–27. https://doi.org/10.1056/NEJMoa1500245 PMID: 26172429

9. Kook JL, Chao SR, Le J, Robinson PA. Impact of the use of procalcitonin assay in hospitalized adult patients with pneumonia at a community acute care hospital. Infect Control Hosp Epidemiol. 2012; 33(4):424–6. https://doi.org/10.1086/664764 PMID: 22416643

10. Bishop BM, Bon JJ, Trienski TL, Pasquale TR, Martin BR, File TM, Jr. Effect of introducing procalcitonin on antimicrobial therapy duration in patients with sepsis and pneumonia in the intensive care unit. Ann Pharmacother. 2014; 48(5):577–83. https://doi.org/10.1177/1060028014520957 PMID: 24519479

11. Koenig SM, Truwit JD. Ventilator-associated pneumonia: diagnosis, treatment, and prevention. Clin Microbiol Rev. 2006; 19(4):637–57. https://doi.org/10.1128/CMR.00051-05 PMID: 17041138

12. Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, et al. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med. 2015; 373(5):415–27. https://doi.org/10.1056/NEJMa1500245 PMID: 26172429

13. Broyles MR. Impact of procalcitonin (PCT)-guided antibiotic management on antibiotic exposure and outcomes: real world evidence. Open Forum Infect Dis. 2017; 4(Suppl1):S484.

14. Stolz D, Smyrnios N, Eggimann P, Pargger H, Thakkar N, Siegemund M, et al. Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. Eur Resp J. 2009; 34(6):1364–75.

15. The Center for Disease Dynamics, Economics and Policy. ResistanceMap. Washington DC and New Delhi: CDDEPP; 2017.

PLOS ONE | https://doi.org/10.1371/journal.pone.0214222  April 23, 2019 14 / 16
18. Chastre J, Wolff M, Fagon J, Chevret S, Thomas F, Wermert D, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA. 2003; 290(19):2588–98. https://doi.org/10.1001/jama.290.19.2588 PMID: 14625336

19. Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. Am J Respir Crit Care Med. 2000; 162:505–511. https://doi.org/10.1164/ajcc.162.2.9909095 PMID: 10934078

20. Van der Maas M, Kip MMA, Mantjes G, Steuten LMG (2015). A procalcitonin algorithm used in adult ICU patients with sepsis saves costs by reducing antibiotic resistance and C. difficile infections. Poster. In: ISPOR 18th Annual European Congress, November 7th–11th, 2015, Milan, Italy.

21. Mitchell BG, Gardner A. Prolongation of length of stay and Clostridium difficile infection: a review of the methods used to examine length of stay due to healthcare associated infections. Antimicrobial Resistance & Infection Control. 2012; 1:14.

22. Kraker MEA de Davey PG, Grundmann H, BURDEN study group. Mortality and hospital stay associated with resistant Staphylococcus aureus and Escherichia coli Bacteremia: estimating the burden of antibiotic resistance in Europe. Plos Medicine. 2011; 8(10):e1001104. https://doi.org/10.1371/journal.pmed.1001104 PMID: 22022233

23. Roberts RR, Hota B, Ahmad I, Scott RD II, Foster SD, Abbasi F et al. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin Infect Dis. 2009; 49:1175–84. https://doi.org/10.1086/605630 PMID: 19739972

24. Lye DC, Earnest A, Ling ML, Lee TE, Yong HC, Fisher DA et al. The impact of multidrug resistance in healthcare-associated and nosocomial Gram-negative bacteraemia on mortality and length of stay: cohort study. Clin Microbiol Infect. 2012; 18:502–508. https://doi.org/10.1111/j.1469-0691.2011.03606.x PMID: 21851482

25. Schuetz P, Christ-Grain M, Thomann R, Falconnier C, Wolbers M, Widmer I, et al. Effect of Procalcitonin-Based Guidelines vs Standard Guidelines on Antibiotic Use in Lower Respiratory Tract Infections: The Pro*HOSP Randomized Controlled Trial. JAMA. 2009; 302(10):1059–66. https://doi.org/10.1001/jama.2009.1297 PMID: 19739090

26. Muller F, Christ-Grain M, Bregenzer T, Krause M, Zimmerli W, Mueller B, et al. Procalcitonin levels predict bacteraemia in patients with community-acquired pneumonia: a prospective cohort trial. Chest. 2010; 138(1):121–9. https://doi.org/10.1378/chest.09-2920 PMID: 20299634

27. Shapiro NI, Wolfe RE, Wright SB, Moore R, Bates DW. Who needs a blood culture? A prospective study. J Emerg Med. 2008; 35(3):255–64.

28. McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, et al. Clinical Practice Guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018; e-pub ahead of print:1–48.

29. Balk RA, Kadri SS, Cao Z, Robinson SB, Lipkin C, Bozzette SA. Effect of Procalcitonin Testing on Health-care Utilization and Costs in Critically Ill Patients in the United States. Chest. 2017; 151(1):23–33. https://doi.org/10.1016/j.chest.2016.06.046 PMID: 27568590

30. The Henry J. Kaiser Family Foundation. State Health Facts Washington DC: KFF; 2017 [Available from: https://www.kff.org/statetables/], accessed on September 26th 2017.

31. Centres for Medicare and Medicaid Services. DMEPOS Fee Schedule Baltimore: CMS; 2017 [Available from: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/DMEPOSFeeSched/ DMEPOS-Fee-Schedule.html], accessed on September 26th 2017.

32. Kall K, McManus ML, McKiernan M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016; 63(5):e61–e111. https://doi.org/10.1093/cid/ciw353 PMID: 27418577

33. Drugs.com. A-Z Drug Index 2017 [Available from: www.drugs.com], accessed on September 26th 2017.

34. Centers for Medicare and Medicaid Services. Clinical Laboratory Fee Schedule Baltimore: CMS; 2017 [Available from: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ ClinicalLabFeeSched/index.html]. Accessed September 20th 2017.

35. Neumann PJ, Ganiats TG, Russell LB, Sanders GD, Siegel JE, editors. Cost-effectiveness in health and medicine. Oxford: Oxford University Press; 2016.

36. Branche AR, Walsh EE, Vargas R, Hubert B, Formica MA, Baran A, et al. Serum procalcitonin measurement and viral testing to guide antibiotic use for respiratory infections in hospitalized adults: a randomized controlled trial. J Infect Dis. 2015; 212(11):1692–700. https://doi.org/10.1093/infdis/jiv252 PMID: 26910632
37. Chu DC, Mehta AB, Walkey AJ. Practice patterns and outcomes associated with procalcitonin use in critically ill patients with sepsis. Clin Infect Dis. 2017; 64(11):1509–15. https://doi.org/10.1093/cid/cix179 PMID: 28329238

38. Longo M, Wickes W, Smout M, Harrison S, Cahill S, White JM. Randomized controlled trial of dexamphetamine maintenance for the treatment of methamphetamine dependence. Addiction. 2010; 105(1):146–54. https://doi.org/10.1111/j.1360-0443.2009.02717.x PMID: 19839966

39. Timbrook T, Maxam M, Bosso J. Antibiotic discontinuation rates associated with positive respiratory viral panel and low procalcitonin results in proven or suspected respiratory infections. Infect Dis Ther. 2015; 4(3):297–306. https://doi.org/10.1007/s40121-015-0087-5 PMID: 26342921

40. Huang DT, Yealy DM, Filbin MR, Brown AM, Chang C-CH, Doi Y et al. Procalcitonin-guided use of antibiotics for lower respiratory tract infection. N Eng J Med. 2018; May 20th:1–14.